Navigation Links
ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Date:10/28/2009

develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for each product;
  • our plans to increase manufacturing capacity for Cinryze and the timing thereof;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring products in clinical development or marketed products.
  • There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. There can be no assurance that we will conduct additional studies or that we will be successful in gaining regulatory approval of Cinryze for ad
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
    2. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
    3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
    4. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
    5. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
    6. ViroPharma Announces Discontinuation of HCV-796 Development
    7. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
    8. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
    9. ViroPharma to Present at the Natixis Bleichroeder Conference
    10. ViroPharma to Present at Three Upcoming Healthcare Conferences
    11. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
    (Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
    (Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
    Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
    ... NATICK, Mass., Feb. 7, 2012 Boston Scientific Corporation (NYSE: ... Leerink Swann 2012 Global Healthcare Conference on February 15 in ... Mahoney, President, and Jeff Capello, Executive Vice President and Chief ... session regarding the Company beginning at approximately 11:00 a.m. ET. ...
    ... Feb. 7, 2012  Cardica, Inc. (Nasdaq: CRDC ) today ... and other conditions, shares of its common stock in an underwritten ... when the offering may be completed, or as to the size ... is acting as sole book-running manager for the offering. ...
    Cached Medicine Technology:Boston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference 2Cardica Announces Proposed Public Offering of Common Stock 2
    (Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
    (Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
    (Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
    (Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
    (Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
    Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
    ... Radioimmunotherapy is a technique used in treating cancer , in ... are injected into patients.// These antibodies target and destroy ... particles . The main advatage of this treatment is ... ,A study in mice showed that this approach could be ...
    ... some of the reasons why hundreds of people// in ... to orthopaedic experts here. ,"Indian orthopaedics is ... complicated surgeries being performed here daily," said Surya Bhan, ... Institute of Medical Sciences (AIIMS) here. ,Bhan ...
    ... of deaths due to alcoholism has raised twofold in the ... that the number of deaths due to alcohol was 4,144 ... by last year. ,According to the experts, the lower ... alcohol consumption. Premature deaths are mainly caused by binge drinking ...
    ... been shown to prevent 70 per cent of cervical ... according to reports from Labor today. ,The government's ... Australian manufacturer CSL to make the vaccine Gardasil freely ... ,Gardasil, the vaccine designed in Australia halts the ...
    ... cells trial will be conducted within weeks on 100 patients ... yesterday.// ,This ?1.2 million trial of stem cells ... marrow will be backed by ?500,000 from philanthropists and aims ... of prompt action to cut deaths and suffering. ...
    ... such as ranitidine (Zantac) and cimetidine (Tagamet)and proton pump ... to increase the risk of cancer of the esophagus or ... H2 blockers and proton pump inhibitors do not increase the ... probably due to other related factors. 'There have been concerns ...
    Cached Medicine News:Health News:A New Option For AIDS Treatment - Radioimmunotherapy 2Health News:Mismanagement of fractures a major concern, say experts 2Health News:Deaths due to heavy drinking has doubled in 15 years 2Health News:Heart Attack Damage Repaired with Stem cells 2Health News:Long-time Gastric Acid Suppression Does Not Increase The Risk Of Cancer 2
    ... Compensating for movement is ... in wheelchairs. Thats why ... exclusive technology to do ... with state-of-the-art technology, these ...
    ... wheelchair scale accommodates standard to extra-wide wheelchairs ... devices. The low-profile, heavy-duty, anodized aluminum weighing ... 1/2" high providing easy access for large ... stainless steel digital readout. The 6772 has ...
    This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
    ... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
    Medicine Products: